Clinical Trial Update: A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating agomelatine 25 or 50 mg versus placebo and paroxetine for major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Agomelatine (agomelatine)
• Paroxetine (Paroxetine hydrochloride)

Snippet

Sponsor: Novartis | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED